个人中心 - 老虎社区

升升点光

IP属地：广东

帖子 · 4帖子 · 4
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- 升升点光升升点光
  ·04-21
  给你糖，让你胖，最后还要卖你减肥药
  减肥药迈入“吃药时代”？礼来口服神药试验成功，股价飙涨创25年新高！
  在公布一种用于2型糖尿病和肥胖治疗的GLP-1药物口服剂型的三期试验取得积极成果后，礼来股价周四暴涨14%，创下近25年来最大单日涨幅。礼来在声明中指出，这是首个成功完成三期试验的小分子口服GLP-1受体激动剂。周四，Viking股价下跌1.7%，Terns上涨4.5%。同时，试验中未出现肝损伤报告，最高剂量下的不良反应导致8%的受试者中止治疗。
  减肥药迈入“吃药时代”？礼来口服神药试验成功，股价飙涨创25年新高！
  838 评论
  1
  分享
  举报
- 升升点光升升点光
  ·2021-11-18
  $SOS Limited(SOS)$毫无底线的跌
  2,426 评论
  2
  分享
  举报
- 升升点光升升点光
  ·2021-08-17
  $维亚生物(01873)$要凉凉了吗？买了后一直跌。。。
  3,470 评论
  点赞
  分享
  举报
- 升升点光升升点光
  ·2021-05-20
  请问为什么委托140却只成交10？还10个扣手续费？
  3,110 评论
  点赞
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3582262299317961","uuid":"3582262299317961","gmtCreate":1619171138262,"gmtModify":1637631494952,"name":"升升点光","pinyin":"ssdgshengshengdianguang","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/c524587525da6d8de422100d47803ba2","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":40,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":7,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.06.02","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.15","exceedPercentage":"80.25%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.09%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"广东","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":3,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":426823891153488,"gmtCreate":1745228815303,"gmtModify":1745231144847,"author":{"id":"3582262299317961","authorId":"3582262299317961","name":"升升点光","avatar":"https://static.tigerbbs.com/c524587525da6d8de422100d47803ba2","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582262299317961","authorIdStr":"3582262299317961"},"themes":[],"htmlText":"给你糖，让你胖，最后还要卖你减肥药","listText":"给你糖，让你胖，最后还要卖你减肥药","text":"给你糖，让你胖，最后还要卖你减肥药","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/426823891153488","repostId":"2529826878","repostType":2,"repost":{"id":"2529826878","kind":"news","pubTimestamp":1745223912,"share":"https://www.laohu8.com/m/news/2529826878?lang=&edition=full","pubTime":"2025-04-21 16:25","market":"us","language":"zh","title":"减肥药迈入“吃药时代”？礼来口服神药试验成功，股价飙涨创25年新高！","url":"https://stock-news.laohu8.com/highlight/detail?id=2529826878","media":"金十数据","summary":"在公布一种用于2型糖尿病和肥胖治疗的GLP-1药物口服剂型的三期试验取得积极成果后，礼来股价周四暴涨14%，创下近25年来最大单日涨幅。礼来在声明中指出，这是首个成功完成三期试验的小分子口服GLP-1受体激动剂。周四，Viking股价下跌1.7%，Terns上涨4.5%。同时，试验中未出现肝损伤报告，最高剂量下的不良反应导致8%的受试者中止治疗。","content":"<html><body><article><p><strong>在公布一种用于</strong>2型糖尿病和肥胖治疗的GLP-1药物口服剂型的三期试验取得积极成果后，<a href=\"https://laohu8.com/S/LLY\">礼来</a>(LLY.N)股价周四暴涨14%，创下近25年来最大单日涨幅。</p><p>据道琼斯市场数据称，上一次股价涨幅如此之大还要追溯到2000年6月29日，当日收涨17.7%。过去五个交易日中，该股上涨了四天，目前在<a href=\"https://laohu8.com/S/161125\">标普500</a>指数中领涨。</p><p>礼来表示，名为orforglipron的药物在三期临床试验中显示出具有统计学意义的积极效果，其安全性表现也与现有注射型GLP-1药物一致。该药物为每日一次的口服治疗方式，在第40周时，能将血糖指标A1C平均降低1.3%至1.6%，同时在最高剂量下平均减重16磅（约7.3公斤）。</p><p>礼来在声明中指出，这是首个成功完成三期试验的小分子口服GLP-1受体激动剂。目前这一类热门新药仅有注射型版本，而口服剂型的出现，被认为将彻底改变格局，因其更易服用，也更容易大规模制造。</p><p>礼来首席执行官大卫·A·里克斯（David A. Ricks）在声明中表示：“我们很高兴看到我们的最新促胰素药物在安全性、耐受性、血糖控制和减重方面都达到了我们的预期，并期待今年晚些时候公布更多数据。”</p><p>“作为每日一次的便捷口服药物，orforglipron若获批，将可以实现大规模制造和推广，为全球患者提供新的治疗选择。”</p><p>美国银行证券（BofA Securities）分析师蒂姆·安德森（Tim Anderson）领衔的团队在报告中称，这些数据“几乎是我们设想的最佳情境——在减重、血糖控制、耐受性和安全性方面表现都很理想”。美银维持对礼来股票的“买入”评级，并给出1000美元的目标价，这较当前股价仍有20%的上涨空间。</p><p>分析师写道：“这可能是大型生物制药公司中最重大、最重要、最受关注的研发管线事件之一，现在已经落地，并且结果令人满意。”</p><p>礼来与丹麦诺和<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>(NVO.N)同为GLP-1领域的领军企业，分别拥有糖尿病药物Mounjaro和减肥药Zepbound。这类药物通过模拟肠道激素来控制食欲，因而大受欢迎，但也导致当前注射型产品供应紧张，预计在口服版本获批后将得以缓解。</p><p>包括Viking <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>（VKTX）和Terns Pharmaceuticals（TERN）在内的多家药企也在竞相开发自己的口服药物。周四，Viking股价下跌1.7%，Terns上涨4.5%。</p><p>诺和诺德在美上市的股票下跌7%。<a href=\"https://laohu8.com/S/JEF\">杰富瑞</a>分析师指出，<strong>礼来的口服药物在糖尿病控制方面与诺和诺德的注射剂</strong>Ozempic不相上下，在减重效果方面也与其Wegovy相当。</p><p>杰富瑞分析师本杰明·杰克逊（Benjamin Jackson）在报告中表示：“这些结果进一步增强我们对GLP-1口服药将占据30%以上市场份额的信心，而诺和诺德目前缺乏具备可行性和可规模化的口服产品，因此其在这一领域所占份额可能有限。”</p><p>该分析师团队给予诺和诺德股票“跑输大盘”评级，相当于“卖出”，并指出“对诺和诺德GLP-1业务增长的担忧可能会因此加剧。”</p><p>礼来的这项三期试验共招募了559名仅靠饮食和锻炼控制血糖仍不理想的2型糖尿病患者，来自美国、中国、印度、日本和墨西哥。试验分为3、12和36毫克剂量组，另设有安慰剂对照组。研究始于2023年，后续数据将在今年晚些时候以及2026年陆续公布。</p><p>值得期待的是，礼来指出，在第40周时，受试者的平均体重减轻尚未达到平台期——这意味着未来仍有继续减重的潜力。</p><p>美银分析师补充称，在最高剂量组中，平均减重为7.9%，超过礼来此前预期的4%至7%范围。同时，试验中未出现肝损伤报告，最高剂量下的不良反应导致8%的受试者中止治疗。</p><p>公司计划在美国糖尿病协会第85届科学年会上展示这些数据，并将在同行评审期刊上发表。</p><p>声明表示：“礼来预计将在今年年底前向全球监管机构提交orforglipron的体重管理适应症申请，并计划于2026年申请其作为2型糖尿病治疗药物的批准。</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>减肥药迈入“吃药时代”？礼来口服神药试验成功，股价飙涨创25年新高！</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n减肥药迈入“吃药时代”？礼来口服神药试验成功，股价飙涨创25年新高！\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-21 16:25 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042116252294dca5d0&s=b><strong>金十数据</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>在公布一种用于2型糖尿病和肥胖治疗的GLP-1药物口服剂型的三期试验取得积极成果后，礼来(LLY.N)股价周四暴涨14%，创下近25年来最大单日涨幅。据道琼斯市场数据称，上一次股价涨幅如此之大还要追溯到2000年6月29日，当日收涨17.7%。过去五个交易日中，该股上涨了四天，目前在标普500指数中领涨。礼来表示，名为orforglipron的药物在三期临床试验中显示出具有统计学意义的积极效果，其...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042116252294dca5d0&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","SGXZ81514606.USD":"大华环球创新基金A Acc USD","BK4007":"制药","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0238689110.USD":"贝莱德环球动力股票基金","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","BK4599":"减肥药","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU1232071149.USD":"AZ FUND 1 GLOBAL GROWTH SELECTOR \"AAZ\" (USDHDG) ACC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0079474960.USD":"联博美国增长基金A","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU0882574139.USD":"富达环球消费行业基金A ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","BK4585":"ETF&股票定投概念","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","SG9999015978.USD":"利安颠覆性创新基金A","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LLY":"礼来","LU2063271972.USD":"富兰克林创新领域基金","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0385154629.USD":"贝莱德营养科学基金A2","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042116252294dca5d0&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2529826878","content_text":"在公布一种用于2型糖尿病和肥胖治疗的GLP-1药物口服剂型的三期试验取得积极成果后，礼来(LLY.N)股价周四暴涨14%，创下近25年来最大单日涨幅。据道琼斯市场数据称，上一次股价涨幅如此之大还要追溯到2000年6月29日，当日收涨17.7%。过去五个交易日中，该股上涨了四天，目前在标普500指数中领涨。礼来表示，名为orforglipron的药物在三期临床试验中显示出具有统计学意义的积极效果，其安全性表现也与现有注射型GLP-1药物一致。该药物为每日一次的口服治疗方式，在第40周时，能将血糖指标A1C平均降低1.3%至1.6%，同时在最高剂量下平均减重16磅（约7.3公斤）。礼来在声明中指出，这是首个成功完成三期试验的小分子口服GLP-1受体激动剂。目前这一类热门新药仅有注射型版本，而口服剂型的出现，被认为将彻底改变格局，因其更易服用，也更容易大规模制造。礼来首席执行官大卫·A·里克斯（David A. Ricks）在声明中表示：“我们很高兴看到我们的最新促胰素药物在安全性、耐受性、血糖控制和减重方面都达到了我们的预期，并期待今年晚些时候公布更多数据。”“作为每日一次的便捷口服药物，orforglipron若获批，将可以实现大规模制造和推广，为全球患者提供新的治疗选择。”美国银行证券（BofA Securities）分析师蒂姆·安德森（Tim Anderson）领衔的团队在报告中称，这些数据“几乎是我们设想的最佳情境——在减重、血糖控制、耐受性和安全性方面表现都很理想”。美银维持对礼来股票的“买入”评级，并给出1000美元的目标价，这较当前股价仍有20%的上涨空间。分析师写道：“这可能是大型生物制药公司中最重大、最重要、最受关注的研发管线事件之一，现在已经落地，并且结果令人满意。”礼来与丹麦诺和诺和诺德(NVO.N)同为GLP-1领域的领军企业，分别拥有糖尿病药物Mounjaro和减肥药Zepbound。这类药物通过模拟肠道激素来控制食欲，因而大受欢迎，但也导致当前注射型产品供应紧张，预计在口服版本获批后将得以缓解。包括Viking Therapeutics（VKTX）和Terns Pharmaceuticals（TERN）在内的多家药企也在竞相开发自己的口服药物。周四，Viking股价下跌1.7%，Terns上涨4.5%。诺和诺德在美上市的股票下跌7%。杰富瑞分析师指出，礼来的口服药物在糖尿病控制方面与诺和诺德的注射剂Ozempic不相上下，在减重效果方面也与其Wegovy相当。杰富瑞分析师本杰明·杰克逊（Benjamin Jackson）在报告中表示：“这些结果进一步增强我们对GLP-1口服药将占据30%以上市场份额的信心，而诺和诺德目前缺乏具备可行性和可规模化的口服产品，因此其在这一领域所占份额可能有限。”该分析师团队给予诺和诺德股票“跑输大盘”评级，相当于“卖出”，并指出“对诺和诺德GLP-1业务增长的担忧可能会因此加剧。”礼来的这项三期试验共招募了559名仅靠饮食和锻炼控制血糖仍不理想的2型糖尿病患者，来自美国、中国、印度、日本和墨西哥。试验分为3、12和36毫克剂量组，另设有安慰剂对照组。研究始于2023年，后续数据将在今年晚些时候以及2026年陆续公布。值得期待的是，礼来指出，在第40周时，受试者的平均体重减轻尚未达到平台期——这意味着未来仍有继续减重的潜力。美银分析师补充称，在最高剂量组中，平均减重为7.9%，超过礼来此前预期的4%至7%范围。同时，试验中未出现肝损伤报告，最高剂量下的不良反应导致8%的受试者中止治疗。公司计划在美国糖尿病协会第85届科学年会上展示这些数据，并将在同行评审期刊上发表。声明表示：“礼来预计将在今年年底前向全球监管机构提交orforglipron的体重管理适应症申请，并计划于2026年申请其作为2型糖尿病治疗药物的批准。","news_type":1,"symbols_score_info":{"LLY":1}},"isVote":1,"tweetType":1,"viewCount":838,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876076821,"gmtCreate":1637247132677,"gmtModify":1637247132677,"author":{"id":"3582262299317961","authorId":"3582262299317961","name":"升升点光","avatar":"https://static.tigerbbs.com/c524587525da6d8de422100d47803ba2","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582262299317961","authorIdStr":"3582262299317961"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SOS\">$SOS Limited(SOS)$</a>毫无底线的跌","listText":"<a href=\"https://laohu8.com/S/SOS\">$SOS Limited(SOS)$</a>毫无底线的跌","text":"$SOS Limited(SOS)$毫无底线的跌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876076821","isVote":1,"tweetType":1,"viewCount":2426,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":839501255,"gmtCreate":1629164454777,"gmtModify":1629164454777,"author":{"id":"3582262299317961","authorId":"3582262299317961","name":"升升点光","avatar":"https://static.tigerbbs.com/c524587525da6d8de422100d47803ba2","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582262299317961","authorIdStr":"3582262299317961"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01873\">$维亚生物(01873)$</a>要凉凉了吗？买了后一直跌。。。","listText":"<a href=\"https://laohu8.com/S/01873\">$维亚生物(01873)$</a>要凉凉了吗？买了后一直跌。。。","text":"$维亚生物(01873)$要凉凉了吗？买了后一直跌。。。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/839501255","isVote":1,"tweetType":1,"viewCount":3470,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":130857171,"gmtCreate":1621525706393,"gmtModify":1621525706393,"author":{"id":"3582262299317961","authorId":"3582262299317961","name":"升升点光","avatar":"https://static.tigerbbs.com/c524587525da6d8de422100d47803ba2","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582262299317961","authorIdStr":"3582262299317961"},"themes":[],"htmlText":"请问为什么委托140却只成交10？还10个扣手续费？","listText":"请问为什么委托140却只成交10？还10个扣手续费？","text":"请问为什么委托140却只成交10？还10个扣手续费？","images":[{"img":"https://static.tigerbbs.com/604f5187fdec066a72b3f03b6f344080","width":"1080","height":"2797"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/130857171","isVote":1,"tweetType":1,"viewCount":3110,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}